In conclusion, this comprehensive network pharmacological analysis proposes numerous testable surmises about the potential molecular mechanisms of XHP formula for the treatment of pancreatic cancer and predicts that quercetin, 17-β-estradiol, ursolic acid, and daidzein are potential bioactive ingredients of XHP, which act on key genes such as EGFR and MAPK1 and regulate many pathways (EGFR/MAPK pathway, IL-17 signaling pathway, NF-κB pathway, pathways in cancer, etc.). Here, EGFR is linked to familial pancreatic carcinoma.